Clinical validation on the PAOLA-1/ENGOT-ov25 cohort of HRD calculation performed with the OncoDEEP® Kit comprehensive genomic panel.

The PAOLA-1/ENGOT-ov25 cohort is a pivotal clinical trial investigating maintenance therapy with olaparib and bevacizumab in patients with advanced ovarian cancer. A key outcome of the study is the significantly improved progression-free survival observed in patients with homologous recombination deficiency (HRD), a condition that impairs the cell’s ability to repair DNA damage via homologous recombination. This deficiency enhances sensitivity to PARP inhibitors such as olaparib. The OncoDeep kit has now achieved clinical validation for HRD detection in this context, confirming its utility in identifying patients who are most likely to benefit from targeted therapies like those evaluated in PAOLA-1.